Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause

PHASE4CompletedINTERVENTIONAL

Enrollment

10,011

Participants

Timeline

Start Date

January 27, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2024

Conditions

COPD Exacerbation

Interventions

DRUG

Long acting muscarinic antagonists (LAMAs) in the evening

LAMAs administered at bedtime (8pm - 2am)

Trial Locations (1)

Herlev-Gentofte Hospital, Copenhagen

All Listed Sponsors

lead

Chronic Obstructive Pulmonary Disease Trial Network, Denmark

OTHER